

# CODEBASE VENTURES INC.

09:41 23 Jan 2020

## Codebase forms Titan Shrooms & Psychedelics to invest in mental health treatments using magic mushrooms

Codebase Ventures Inc (CSE:CODE) (OTCMKTS:BKLLF), a venture capital company investing in early-stage technology and cannabis companies, announced Thursday that it has formed a wholly-owned subsidiary named Titan Shrooms & Psychedelics Inc to spearhead its investments into the exciting, emerging market for mental health treatments using mushrooms and psychedelics.

"Mushrooms and psychedelics fit our mandate as an emerging sector with tremendous potential for those suffering from certain mental health issues, as was well documented on 60 Minutes at the end of December," said Brian Keane, a director with Codebase Ventures.

For most, psychedelic drugs conjure up images of the 1960's, hippies tripping out on LSD or magic mushrooms. However, CBS correspondent Anderson Cooper's 60 Minutes program drills deep into how cancer patients with painful anxiety over their illness have found more peaceful acceptance after participating in a study that involved intensive therapy and being given a drug that was once a symbol of the 60's counterculture.

### READ: Codebase Ventures to focus on mental health treatments using mushrooms and psychedelics

Early studies are finding that psilocybin - the active agent in magic mushrooms could treat addiction, depression and anxiety.

Some of the country's leading medical research centers are looking to see if psychedelic drugs and intense therapy can help people quit smoking and worry less.

"We are encouraged by the fact that the FDA has granted breakthrough therapy status for trials into psilocybin, the naturally occurring psychoactive compound in psychedelic mushrooms," noted Keane.

### Bodes well for psilocybin therapies

"This bodes well for innovative therapies that can help millions of people with mental health conditions ranging from treatment-resistant depression to anxiety and addiction — and there are indications that the treatments could become approved at some point in 2021 as reported in Rolling Stone," he added.


According to Rolling Stone magazine, for the first time in US history, a psychedelic drug is on the fast track to getting approved for treating depression by the federal government. Last October, Compass Pathways, a UK-based company that researches and develops mental health treatments, announced the US Food and Drug Administration granted it what's called a "breakthrough therapy designation" for its trials into psilocybin, the psychoactive ingredient in psychedelic mushrooms.

If Compass is successful, psilocybin will be approved by the FDA for patients with treatment-resistant depression, or

**Price:** 0.05

**Market Cap:** \$2.31 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** CODE

**Listing:** CSE

**52 week High Low**  
0.35 0.045

**Sector:** Financial Services

**Website:** www.codebase.ventures

#### Company Synopsis:

Codebase Ventures Inc. is a small, hands-on team of financial and technology experts who invest early in great ideas. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders.

action@proactiveinvestors.com

patients who have not responded to traditional anti-depressants.

### **Strong investment mandate**

Codebase's subsidiary Titan Shrooms & Psychedelics will focus on identifying investment opportunities that meet with the company's investment mandate. The company may invest up to C\$2 million in such opportunities.

The company said Titan Shrooms & Psychedelics is "actively seeking" investment opportunities at the forefront of the mushroom and micro-dosing psychedelic healthcare sector. Codebase is not averse to taking management positions in companies in which they are investing, added the company.

Codebase Ventures, which consists of a small, hands-on team of financial and technology experts, invests in emerging technologies. It makes strategic investments in ambitious founders who aim to upend large markets.

Contact the author Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CODEBASE VENTURES INC. named herein, including the promotion by the Company of CODEBASE VENTURES INC. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).